Register for a free European Market Report Suite for Urological Devices brochure or synopsis
According to a new series of reports by iData Research (www.idataresearch.com), although the European market for urological devices is highly commoditized, an increasing global awareness of infection rates is helping to drive preferences for single-use devices. This results in higher unit sales and growth in market value. While each individual segment is expected to exhibit growth at varying levels, the overall market will continue to increase to meet a rising demand for urological procedures.
Growth in procedure numbers for each treatment type is expected to be positive. This will lead to a stable distribution in procedure share across treatment types. Over 2.5 million urological procedures were performed in Europe last year. Stone management procedures accounted for the largest portion of all types. This was followed by prostate cancer, interventional BPH procedures and nephrostomy procedures.
The urinary catheter segment comprises the largest portion of the total urological market due to the wide range of uses for urinary catheters and is expected to exhibit strong growth. Hydrophilic catheters are expected to show the strongest growth, closely mirroring that of the overall market.
“The urinary catheter market will experience continued growth as the number of elderly patients requiring catheterization gradually increases,” explains Dr. Kamran Zamanian, CEO of iData. “By 2022, the market for urinary catheters in Europe will have surpassed the €1.2 billion mark.”
The market for urological endoscopes is experiencing the highest level of growth. This market is expected to grow at least three times faster than any other segment in the overall urological device market in Europe. Growth will be sustained by the range of procedures that require urological endoscopes, each of which are expected to experience increasing demand.
Coloplast is the leading competitor in the European urological device market, primarily attributed to its success in the urinary catheter market. Coloplast was also prominent in the markets for nephrostomy devices, urinary incontinence slings, stone treatment devices and erectile dysfunction devices. Coloplast and Wellspect HealthCare are the two dominant players in the European urinary catheter market.
Other market leaders include Teleflex, Hollister, C. R. Bard and Boston Scientific, with most competitors having presence to some degree in the urinary catheter market. Boston Scientifics’ acquisition of American Medical Systems male urology portfolio in March 2015 was fundamental in helping them achieve a dominant position in several segments of the European urology market. Additional competitors in the European urological market include Karl Storz, Olympus, Manfred Sauer, Lumenis, Covidien, Richard Wolf, Cook Medical, Dornier MedTech, Eckert & Ziegler BEBIG and GE Healthcare (Oncura) among others.
For Further Information
More on the urological device market in Europe can be found in a series of reports published by iData Research entitled the European Market Report Suite for Urological Devices.